*|MC:SUBJECT|*

 

Dear Investor,

Last week, President Trump signed an executive order that sounds like a joke.

It isn’t.

He ordered every federal agency to stop saying “artificial intelligence.” From now on, it’s “Super Intelligence.”

Then on Sunday, he launched a “Super Intelligence Force” to make sure, in his words, that “America continues to lead the World in Super Intelligence, which many say is bigger than the Industrial Revolution, and the Internet.”

The biggest names in tech showed up at the White House the same week to sign a separate accord.

But here’s the line most investors skipped.

The White House says its push is meant to “accelerate breakthroughs in science, medicine, energy, and manufacturing.” 

Medicine is where this stops being a chatbot story… and starts becoming a drug story.

And I’ve found a tiny Nasdaq company that has spent 20 years building the biology layer this kind of AI needs, long before Washington gave it a new name.

19 of the world’s 20 biggest drug companies already work with it.

Its AI-designed candidates matched or beat semaglutide, the molecule behind Ozempic, in independent lab tests.

And the whole company trades for about $70 million.

Get the name and ticker here.
REVEAL THE TICKER

Sincerely, 

WSI News
 
IMPORTANT NOTICE AND DISCLAIMER: All investments are subject to risk, which must be considered on an individual basis before making any investment decision. This paid advertisement includes a stock profile of MindWalk Holdings Corp. (Nasdaq: HYFT). Wall Street Investor is an investment newsletter being advertised herein. This paid advertisement is intended solely for information and educational purposes and is not to be construed under any circumstances as an offer to sell or a solicitation of an offer to purchase any securities. In an effort to enhance public awareness, MindWalk Holdings Corp. (Nasdaq: HYFT) is the sole source of funds for a budget of approximately $450,000 provided to the advertising agency to cover the costs associated with creating, printing and distribution of this advertisement. In addition, Wall Street Investor may receive subscription revenue in the future from new subscribers as a result of this advertisement for its newsletter. The advertising agencies will retain any excess sums after all expenses are paid. While this advertisement is being disseminated and for a period of not less than 90 days thereafter, Wall Street Investor, the advertising agencies, and their respective officers, principals, or affiliates will not sell securities of MindWalk Holdings Corp. (Nasdaq: HYFT). If successful, this advertisement will increase investor and market awareness of MindWalk Holdings Corp. (Nasdaq: HYFT) and its securities, which may result in an increased number of shareholders owning and trading the securities, increased trading volume, and possibly an increase in share price, which may be temporary. This advertisement, the advertising agencies and Wall Street Investor do not purport to provide a complete analysis of MindWalk Holdings Corp. (Nasdaq: HYFT) or its financial position. They are not, and do not purport to be, broker-dealers or registered investment advisors. This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a registered broker-dealer or registered investment advisor or, at a minimum, doing your own research if you do not utilize an investment professional to make decisions on what securities to buy and sell, and only after reviewing the financial statements and other pertinent publicly-available information about MindWalk Holdings Corp. (Nasdaq: HYFT). Further, readers are specifically urged to read and carefully consider the Risk Factors identified and discussed in MindWalk Holdings Corp. (Nasdaq: HYFT) SEC filings. Investing in microcap securities such as MindWalk Holding Corp. (Nasdaq: HYFT) is speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the advertising agencies and Wall Street Investor cannot guarantee the accuracy or completeness of the information and are not responsible for any errors or omissions. This advertisement contains forward-looking statements, including statements regarding expected continual growth of MindWalk Holdings Corp. (Nasdaq: HYFT) and/or its industry. The advertising agencies and Wall Street Investor note that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect MindWalk Holdings Corp. (Nasdaq: HYFT) actual results of operations. Factors that could cause actual results to vary include the size and growth of the market for Mindwalk Holdings Corp. (Nasdaq: HYFT) products and/or services, the company’s ability to fund its capital requirements in the near term and long term, federal and state regulatory issues, pricing pressures, etc. Wall Street Investor is the publisher’s trademark. All trademarks used in this advertisement other than Wall Street Investor are the property of their respective trademark holders and no endorsement by such owners of the contents of this advertisement is made or implied. The advertising agencies Wall Street Investor are not affiliated, connected, or associated with, and are not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made to any rights in any third-party trademarks.
 
 
 
 

Notice: Please understand that by opting out from future emails from this advertiser, you are transferring or
authorizing the transfer of your email address to the advertiser listed above. Zacks has no control over how
your email address is used by the advertiser or other third parties. Accordingly, Zacks disclaims all
responsibility and liability arising from the subsequent use of your email address that is made possible by
your submission of your email address above. You are receiving this email from Zacks Investment Research
because you chose to receive messages from Zacks’ partners on the Zacks web site(s). Please note that
Zacks does not produce or endorse this product, and assumes no responsibility for the use thereof.

Your privacy is important to us. Click here to see our Privacy Policy: https://www.zacks.com/privacy.php
If you do not wish to receive further email solicitations from Zacks on behalf of its partners, please click here
to unsubscribe.

Zacks Investment Research
10 S. Riverside Plaza, Suite 1600
Chicago, IL 60606